RedHill Biopharma (RDHL) Other financing activities (2014 - 2022)

RedHill Biopharma (RDHL) has 8 years of Other financing activities data on file, last reported at -$8.3 million in Q4 2022.

• On a quarterly basis, Other financing activities changed N/A year-over-year to -$8.3 million in Q4 2022; TTM through Dec 2022 was -$13.4 million, a 435.05% decrease from a year earlier, with the FY2024 full-year figure at $790000.0, down 94.81% from the prior year.
• Other financing activities for Q4 2022 stood at -$8.3 million, down from -$3.1 million in the prior quarter.
• Over the last five years, Other financing activities for RDHL reached as high as $4.0 million in Q3 2020 and fell as low as -$20.0 million in Q1 2020.
• Historically, Other financing activities has averaged -$2.5 million across 4 years, with a median of $60000.0 in 2018.
• Across the five-year window, Other financing activities jumped 128.13% in 2018 and plunged 1837.72% in 2022, its largest moves.
• Year by year, Other financing activities stood at $6000.0 in 2018, then surged by 66566.67% to $4.0 million in 2020, then tumbled by 83.38% to $665000.0 in 2021, then tumbled by 1347.82% to -$8.3 million in 2022.
• Per Business Quant data, the three most recent Other financing activities figures were -$8.3 million in Q4 2022, -$3.1 million in Q3 2022, and -$2.0 million in Q2 2022.